Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2014

01-03-2014 | Article

Pneumocystis jirovecii (Pj) quantitative PCR to differentiate Pj pneumonia from Pj colonization in immunocompromised patients

Authors: M. Maillet, D. Maubon, J. P. Brion, P. François, L. Molina, J. P. Stahl, O. Epaulard, A. Bosseray, P. Pavese

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2014

Login to get access

Abstract

Conventional polymerase chain reaction (PCR) in respiratory samples does not differentiate between Pneumocystis pneumonia (PCP) and Pneumocystis jirovecii (Pj) colonization. We used Pj real-time quantitative PCR (qPCR) with the objective to discriminate PCP from Pj colonization in immunocompromised patients. All positive Pj qPCR [targeting the major surface glycoprotein (MSG) gene] obtained in respiratory samples from immunocompromised patients presenting pneumonia at the Grenoble University Hospital, France, were collected between August 2009 and April 2011. Diagnoses were retrospectively determined by a multidisciplinary group of experts blinded to the Pj qPCR results. Thirty-one bronchoalveolar lavages and four broncho aspirations positive for the Pj qPCR were obtained from 35 immunocompromised patients. Diagnoses of definite, probable, and possible PCP, and pneumonia from another etiology were retrospectively made for 7, 4, 5, and 19 patients, respectively. Copy numbers were significantly higher in the “definite group” (median 465,000 copies/ml) than in the “probable group” (median 38,600 copies/ml), the “possible group” (median 1,032 copies/ml), and the “other diagnosis group” (median 390 copies/ml). With the value of 3,160 copies/ml, the sensitivity and specificity of qPCR for the diagnosis of PCP were 100 % and 70 %, respectively. With the value of 31,600 copies/ml, the sensitivity and specificity were 80 % and 100 %, respectively. The positive predictive value was 100 % for results with more than 31,600 copies/ml and the negative predictive value was 100 % for results with fewer than 3,160 copies/ml. qPCR targeting the MSG gene can be helpful to discriminate PCP from Pj colonization in immunocompromised patients, using two cut-off values, with a gray zone between them.
Literature
1.
go back to reference Kelley CF, Checkley W, Mannino DM, Franco-Paredes C, Del Rio C, Holguin F (2009) Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii pneumonia in the United States (1986 to 2005). Chest 136:190–197PubMedCrossRef Kelley CF, Checkley W, Mannino DM, Franco-Paredes C, Del Rio C, Holguin F (2009) Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii pneumonia in the United States (1986 to 2005). Chest 136:190–197PubMedCrossRef
2.
go back to reference Mansharamani NG, Garland R, Delaney D, Koziel H (2000) Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 118:704–711PubMedCrossRef Mansharamani NG, Garland R, Delaney D, Koziel H (2000) Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 118:704–711PubMedCrossRef
4.
go back to reference Flori P, Bellete B, Durand F et al (2004) Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 53:603–607PubMedCrossRef Flori P, Bellete B, Durand F et al (2004) Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 53:603–607PubMedCrossRef
5.
go back to reference Botterel F, Cabaret O, Foulet F, Cordonnier C, Costa JM, Bretagne S (2012) Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients. J Clin Microbiol 50(2):227–231PubMedCentralPubMedCrossRef Botterel F, Cabaret O, Foulet F, Cordonnier C, Costa JM, Bretagne S (2012) Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients. J Clin Microbiol 50(2):227–231PubMedCentralPubMedCrossRef
6.
go back to reference Durand-Joly I, Chabé M, Soula F, Delhaes L, Camus D, Dei-Cas E (2005) Molecular diagnosis of Pneumocystis pneumonia. FEMS Immunol Med Microbiol 45:405–410PubMedCrossRef Durand-Joly I, Chabé M, Soula F, Delhaes L, Camus D, Dei-Cas E (2005) Molecular diagnosis of Pneumocystis pneumonia. FEMS Immunol Med Microbiol 45:405–410PubMedCrossRef
8.
go back to reference Chumpitazi BFF, Flori P, Kern JB et al (2011) Characteristics and clinical relevance of the quantitative touch-down major surface glycoprotein polymerase chain reaction in the diagnosis of Pneumocystis pneumonia. Med Mycol Oct 49:704–713 Chumpitazi BFF, Flori P, Kern JB et al (2011) Characteristics and clinical relevance of the quantitative touch-down major surface glycoprotein polymerase chain reaction in the diagnosis of Pneumocystis pneumonia. Med Mycol Oct 49:704–713
9.
go back to reference Carmona EM, Limper AH (2011) Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis 5:41–59PubMedCrossRef Carmona EM, Limper AH (2011) Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis 5:41–59PubMedCrossRef
10.
go back to reference Morris A, Wei K, Afshar K, Huang L (2008) Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 197:10–17PubMedCrossRef Morris A, Wei K, Afshar K, Huang L (2008) Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 197:10–17PubMedCrossRef
11.
go back to reference Ponce CA, Gallo M, Bustamante R, Vargas SL (2010) Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 50:347–353PubMedCrossRef Ponce CA, Gallo M, Bustamante R, Vargas SL (2010) Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 50:347–353PubMedCrossRef
14.
go back to reference Calderon EJ, Dei-Cas E (2010) Pneumocystis infection: unraveling the colonization-to-disease shift. Expert Rev Anti Infect Ther 8(3):259–262PubMedCrossRef Calderon EJ, Dei-Cas E (2010) Pneumocystis infection: unraveling the colonization-to-disease shift. Expert Rev Anti Infect Ther 8(3):259–262PubMedCrossRef
15.
go back to reference Mekinian A, Durand-Joly I, Hatron PY et al (2011) Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology (Oxford) 50:569–577CrossRef Mekinian A, Durand-Joly I, Hatron PY et al (2011) Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology (Oxford) 50:569–577CrossRef
16.
go back to reference Medrano FJ, Montes-Cano M, Conde M et al (2005) Pneumocystis jirovecii in general population. Emerg Infect Dis Feb 11(2):245–250CrossRef Medrano FJ, Montes-Cano M, Conde M et al (2005) Pneumocystis jirovecii in general population. Emerg Infect Dis Feb 11(2):245–250CrossRef
17.
go back to reference Maskell NA, Waine DJ, Lindley A et al (2003) Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 58:594–597PubMedCrossRef Maskell NA, Waine DJ, Lindley A et al (2003) Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 58:594–597PubMedCrossRef
18.
go back to reference Larsen HH, Masur H, Kovacs JA et al (2002) Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol 40(2):490–494PubMedCentralPubMedCrossRef Larsen HH, Masur H, Kovacs JA et al (2002) Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol 40(2):490–494PubMedCentralPubMedCrossRef
19.
go back to reference Asai N, Motojima S, Ohkuni Y et al (2012) Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection. J Infect Chemother 18(6):898–905PubMedCrossRef Asai N, Motojima S, Ohkuni Y et al (2012) Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection. J Infect Chemother 18(6):898–905PubMedCrossRef
20.
go back to reference Thomas CF Jr, Limper AH (2007) Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nature 5(4):298–308 Thomas CF Jr, Limper AH (2007) Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nature 5(4):298–308
21.
go back to reference Summah H, Zhu YG, Falagas ME, Vouloumanou EK, Qu JM (2013) Use of real-time polymerase chain reaction for the diagnosis of Pneumocystis pneumonia in immunocompromised patients: a meta-analysis. Chin Med J (Engl) 126(10):1965–1973 Summah H, Zhu YG, Falagas ME, Vouloumanou EK, Qu JM (2013) Use of real-time polymerase chain reaction for the diagnosis of Pneumocystis pneumonia in immunocompromised patients: a meta-analysis. Chin Med J (Engl) 126(10):1965–1973
22.
go back to reference Alanio A, Desoubeaux G, Sarfati C et al (2011) Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 17:1531–1537PubMedCrossRef Alanio A, Desoubeaux G, Sarfati C et al (2011) Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 17:1531–1537PubMedCrossRef
23.
go back to reference Matsumura Y, Ito Y, Iinuma Y et al (2012) Quantitative real-time PCR and the (1→3)-β-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. Clin Microbiol Infect 18(6):591–597PubMedCrossRef Matsumura Y, Ito Y, Iinuma Y et al (2012) Quantitative real-time PCR and the (1→3)-β-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. Clin Microbiol Infect 18(6):591–597PubMedCrossRef
25.
go back to reference Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A (2008) Contribution of the (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 46:1009–1013PubMedCentralPubMedCrossRef Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A (2008) Contribution of the (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 46:1009–1013PubMedCentralPubMedCrossRef
26.
go back to reference Onishi A, Sugiyama D, Kogata Y et al (2012) Diagnostic accuracy of serum 1,3-β-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 50(1):7–15PubMedCentralPubMedCrossRef Onishi A, Sugiyama D, Kogata Y et al (2012) Diagnostic accuracy of serum 1,3-β-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 50(1):7–15PubMedCentralPubMedCrossRef
Metadata
Title
Pneumocystis jirovecii (Pj) quantitative PCR to differentiate Pj pneumonia from Pj colonization in immunocompromised patients
Authors
M. Maillet
D. Maubon
J. P. Brion
P. François
L. Molina
J. P. Stahl
O. Epaulard
A. Bosseray
P. Pavese
Publication date
01-03-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2014
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-013-1960-3

Other articles of this Issue 3/2014

European Journal of Clinical Microbiology & Infectious Diseases 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.